Radiopharmacuetical Platforms for Theranostic Precision Oncology

• 5807 Synergistic integration of nanobodies and a specialized linker library: A novel radionuclide drug conjugate (RDC) platform paving the way for next-generation radiotherapeutics with optimal druggability and therapeutic index Chong Liu, Zengyan Mu, Sipeng Li, Qingsong Wu, Yajun Sun, Paul H. Song, Gang Qin
• 5810 [ 212 Pb]Pb-AG1206, A novel fibroblast activation protein-targeted radioligand therapy demonstrated excellent efficacy and safety profile Xin Gan, Tao Robert Wu, Miaomiao Song, Shaohua Xu, Guiyu Liu, Vivi Yang, Jinpeng Liu, Xuefei Li, Hu Li, Zhen Cheng, Maijing Liao
• 5811 · PDF Preclinical evaluation of [ 212 Pb]Pb-AG1002, a next generation SSTR2-targeting, non-agonist radiopharmaceutical Xuexiang Zhang, Xuefei Li, Shaohua Xu, Xiao Tang, Xiang Gu, Vivi Yang, Guiyu Liu, Maijing Liao, Tao Robert Wu, Xin Gan
• 5812 Preclinical evaluation of [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 in mice bearing castration-resistant prostate adenocarcinoma patient-derived xenografts Denis Beckford-Vera, Jaeho Lee, Kyle Monger, Erin Kosmowski, Kayla Cotton, Sebastian Brabetz, Markus Hippich, Sarah Maenhout, Paul Heverly, Maria Mancini
• 5813 · PDF Mass dose effects of the immunotheranostic [ 89 Zr]Zr-LNTH-2403 by PET/CT and dosimetry in non-human primates Hansel Comas Rojas, Marcus Lindsey, David Ulmert, Abigail Hasson, Aseem U. Anand, Daniel L. Thorek, Reinier Hernandez
• 5814 · PDF Towards treating prostate cancer with 188 ReO 4 - using an engineered human sodium/iodide symporter (NIS) protein Haswitha Sabbineni, Alejandro Llorente-Esteban, Alejandra Paola Torres-Manzo, Dila Karakas, David Lopez-Gonzalez, Vengatesh Kumar Raja, Mohammed Noor Tantawy, Todd Giorgio, Nancy Carrasco
• 5815 · PDF pH-targeted gadolinium-based nanoparticles for enhanced radiotherapy Jessica Wen, Yuwei Xue, Wu Liu, Guillem Pratx
• 5816 · PDF A novel NTSR1-targeting diagnostic radioligand SKL35502 for noninvasive solid tumor imaging Jungtae Na, Taeyun Lee, Seona Jeon, Hyunseok Lee, Sunghak Lee, Sungwan Hwang, Jungshin Park
• 5817 A novel NTSR1-targeting alpha radiotherapeutic SKL35501 demonstrating potent anti-tumor efficacy in HCT116 colorectal tumor model Jungtae Na, Taeyun Lee, Seona Jeon, Hyunseok Lee, Sunghak Lee, Sungwan Hwang, Jungshin Park
• 5818 · PDF De novo protein design of calreticulin binders for theranostic applications Luke Rathbun, Yuvasri Golivi, Rachael Guenter, J. Bart Rose, Benjamin Larimer
• 5819 PD-L1 targeted radiotherapy can reduce tumor burden and delay tumor growth in a mouse model of triple-negative breast cancer Jonathan Moye, Hailey Houson, Sharmila Sridhar, Sherin James, Jason M. Warram, Suzanne E. Lapi, Anna G. Sorace
• 5820 Biodistribution analysis of Leutetium-177 radiopharmaceuticals in mammary, prostate, and glioblastoma models using Alpha-SPECT Mini and gamma counts Kathryn R. Meshaw, William F. Durham, Karsten E. Fynboe, Tyler Rowe, Jacob C. Hauser, Joseph P. Kolb, Kenneth A. Meshaw, Stephanie M. Fogerson, Beth A. Hollister
• 5821 Utilize a soluble T-cell receptor TCR targeting tumor intracellular antigen PRAME to develop therapeutic and radioactive diagnostic agents for PRAME-positive tumors Yujun Huang, Xiao Liang, Yajuan Xue
• 5822 Efficacy of targeted radionuclide therapy Using 131 I-FAPi dimers labeled via tetrazine ligation in a human glioblastoma xenograft model Umberto Maria Battisti, Marcel Martin, Vladimir Shalgunov, Filipe Elvas, Alan Miranda, Andreas Jensen, Matthias Herth
• 5824 First target disclosure for the preclinical development of ATNM-400, a first-in-class actinium-225 radioconjugate with pan-tumor efficacy in solid tumors Amanda S. Chin, Sumit Mukherjee, Jason Li, Karina Peregrina, Debbie Lewis, Le-Cun Xu, Dhiren Patel, Madhuri Vusirikala, Monideepa Roy, Adeela Kamal
• 5825 · PDF Discovery of FL-261 as a theranostic RDC vector for the treatment of c-MET overexpression cancers Junyu Yang, Guangcheng Jiang, Jiajia Xia, Juan Zhang, Fa Liu
• 5826 · PDF RT01: A novel anti-TF, radionuclide drug conjugate (RDC) for theranostic precision oncology Yi Zhao, Huahua Hao, Xin Yang, Weiwei Pan, XinxinLiang, Quanai Zhang, Xiaoxia Liu, Jingting Cui, Elizabeth Wu, Zhican Qu
• 5827 Actimab-A, a CD33-targeted actinium-225 radioconjugate, drives mutation-agnostic anti-leukemic activity and synergizes with standard therapies in AML through transcriptional reprogramming Amanda S. Chin, Merve Sahin, Jason Li, Le-Cun Xu, Monideepa Roy, Madhuri Vusirikala, Kaitlyn H. Ko, Wenbin Xiao, Adeela Kamal, Sheng F. Cai

在完整检索应用中浏览本分会场 →